Skip to main content
OpenTrials
Completed

NCT Number: NCT03860064

Aneuploidy Rates of in Vitro Matured Oocytes

In general, nearly 85% of retrieved oocytes are mature and reproductively useful after the retrieval, whereas the remaining percentage are still at metaphase I or germinal vesicle stage (MI: 4% and GV: 11 %, respectively).

The objective of our study is to assess if immature oocytes co-cultured with autologous cumulus cells is a safer strategy than just leaving the oocytes in standard culture.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Aneuploidy Chromosome Aberrations Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year–35 year

Sex eligibility

Female

Study type

Observational

Primary location

Ivi Barcelona

Barcelona, 08017, Spain

About this study

Under controlled ovarian stimulation, patients with normal functional ovarian reserves produce a good number of oocytes at retrieval. However, in addition to quantity, oocyte maturity is an important variable for the success of reproductive technologies. In general, nearly 85% of retrieved oocytes are mature and reproductively useful, whereas the remaining percentage are still at metaphase I or germinal vesicle stage (MI: 4% and GV: 11 %, respectively). Due to the limited expectations held for in vitro maturation in said stimulated cycles, the rescue of immature oocytes is not widely used in current clinical practice and these oocytes are usually discarded due to the possibility of abnormal embryonic development or an increased rate of abortion.

The objective of our study is to assess if immature oocytes co-cultured with autologous cumulus cells is a safer strategy than just leaving the oocytes in standard culture.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18-35-year-old women
  • BMI: >18 and < 30 kg/m2
  • Normal female karyotype
  • Normal uterus and ovaries at transvaginal ultrasound

Exclusion criteria

  • > 35 years
  • PCO syndrome carriers
  • Null follicle aspiration
  • History of chemotherapy or radiotherapy

Treatment and study plan

Non intervention

Other

Non

Primary outcomes

  1. Aneuploidy rate

    Time frame: The moment that the PB is extruded (between 1 hour and 50 hours after the denudation)

    Aneuploidy rate of the PB

Sponsors and collaborators

Lead sponsor

IVI Barcelona

Other

Registry information

Acronym: IVM

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Mar 1, 2019
Registry last updated
Nov 19, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.